October 2015

New Product - Cyramza

Cyramza (ramucirumab [rmc]) is a human IgG₁ monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology. Ramucirumab is a human receptor targeted antibody that specifically binds VEGF receptor 2 and blocks binding of VEGF‑A, VEGF‑C, and VEGF‑D. Cyramza, in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. Cyramza, as monotherapy, is also indicated for the treatment of adults with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate. Cyramza is available as a 10 mg/mL concentrate for infusion in a 10 mL vial in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au